Strikingly, preclinical CDX and PDX models showed that RO‐3306, a selective CDK1 inhibitor, had a remarkable effect of restoring the sensitivity of CRC cells to oxaliplatin. The gene discussed is CDK1; the disease is colorectal carcinoma.